Code Bio Overview
- Founded
-
2020
- Status
-
Private
- Employees
-
37
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$75M
- Investors
-
11
Code Bio General Information
Description
Developer of a non-viral gene therapy designed to treat serious and life-threatening genetic diseases. The company's therapy is leveraging a novel proprietary multivalent synthetic DNA delivery platform, 3DNA, that can overcome many of the challenges inherent with viral-based gene therapies, such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity, enabling physicians to treat patients with rare and prevalent genetic diseases.
Contact Information
Website
www.codebiotx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 2801 Sterling Drive
- Hatfield, PA 19440
- United States
+1 (215) 000-0000
Code Bio Timeline
Code Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 25-May-2022 | $75M | 0000 | 00000 | Completed | Generating Revenue |
| 1. Seed Round | 20-Apr-2021 | 0000 | 0000 | 0000 | Completed | Generating Revenue |
Code Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series A-1 | 0,000,000 | 00.000000 | 00 | 000.0 | 000.0 | 00 | 000.0 | 00.000 |
| Seed | 1,535,445 | $0.000010 | 8% | $6.51 | $6.51 | 1x | $6.51 | 13.01% |
Code Bio Patents
Code Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4054635-A1 | Brain-specific angiogenesis inhibitor 1 (bai1) antibodies and uses thereof | Pending | 04-Nov-2019 | 000000000 | |
| JP-2023500530-A | Brain-specific angiogenesis inhibitory factor 1 (bai1) antibody and use thereof | Pending | 04-Nov-2019 | 000000000 | |
| US-20210130448-A1 | Brain-specific angiogenesis inhibitor 1 (bai1) antibodies and uses thereof | Pending | 04-Nov-2019 | C07K16/28 |
Code Bio Executive Team (8)
Code Bio Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brian McVeigh | Self | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
| Diana Bernstein Ph.D | Northpond Ventures | Board Member | 000 0000 |
| Dmitry Kuzmin Ph.D | 4BIO Capital | Board Member | 000 0000 |
| Edward Mathers | New Enterprise Associates | Board Member | 000 0000 |
| Joseph Truitt | Self | Board Member | 000 0000 |
Code Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Code Bio Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Amgen Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Hatteras Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Northpond Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| UCB Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| 4BIO Capital | Venture Capital | Minority | 000 0000 | 000000 0 |